Breaking News: 89bio Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants, and Warrants!
89bio, Inc. Making Waves in the Biopharmaceutical Industry A New Player in Town San Francisco, June 29, 2022 – 89bio, Inc. (“89bio”) (Nasdaq: ETNB) has been making headlines in the biopharmaceutical industry with its innovative approaches and cutting-edge research. As a clinical-stage biopharmaceutical company, 89bio is focused on the development… The Company’s Mission 89bio’s mission…